Climb Bio, Inc.
CLYM
Jodie situation report
Climb Bio, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
- CLYM's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CLYM's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind CLYM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
JBIOJade Biosciences, Inc.competitorMay 7, 2026 ▾
“We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Biogen Inc., Biohaven, Ltd., Calliditas Therapeutics AB, Climb Bio, Inc., Novartis AG, Otsuka Pharmaceu…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CLYM is currently a Follower in the organic co-movement group Biotech and Gold. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CLYM; it is not active in the latest market snapshot.